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Materials and methods. We evaluated all the patients who received a High Dose Rate (HDR) boost in our department
between October 2008 and September 2012. All of them were treated with external radiotherapy to the whole breast
before the boost. We evaluated acute and long term toxicity. Then, we compared the results between the women treated
in a conventional way versus hypofractionated patients. Prescription dose was based on the modiﬁed Paris dosimetry
treatment.
Results. We treated 379 boosts. 67.3% were hypofractionated and 32.7% were conventional treatments. 50.4% were right
breast cancers and the tumor bed was localized in upper external quadrant in 37.5% of patients. 59.9% received an 8Gy
boost. The mean implant volume (isodose of the 90% of the prescribed dose) was 8.68 cm3. Regarding toxicity, our results
do not differ much more than the presented in literature. We have less than 5% acute toxicity in terms of infection,
bleeding or acute pain. Chronically, most of the patients experience different grades of pain associated to ﬁbrosis, but it
doesn’t inﬂuence their daily lives in the majority of them. No grade 3 or 4 toxicity was reported. If we compare the results
between the groups (conventional and hypofractionated), we did not ﬁnd any statistically signiﬁcant difference in terms of
toxicity.
Conclusion. HDR-BRT is a safe and not much toxic way to administer the boost over the tumor bed in patients in indication. The
ﬁnal toxicity outcomes are not inﬂuenced by the fractionation of the previous whole breast treatment.
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Introduction. Adjuvant vaginal brachytherapy in gynaecological cancer alone or combined with EBRT is a standard procedure. The
vaginal brachytherapy HDR alone with 192 Ir is a technique with minimal side effects, can be performed in an outpatient. In
patients with limited disease in endometrial, vaginal and cervix uterine. The aim of our study is to describe our experience with
vaginal brachytherapy alone.
Materials and methods. We retrospectively analyzed 130 patients diagnosed with endometrial, vagina and cervix cancer. Between
January 2008 and January 2013. Treated with brachytherapy alone. We performed a descriptive study of our patients.
Results. 130 patients mean age 63.5 (32–85). 93.8% with endometrial cancer, cervix 4.6% and 1.5% vaginal cancer. Distributed
under the current classiﬁcation of FIGO. The mean follow-up 34.7 months (7–65), 90% adenocarcinoma, and 96.9% G1–G2. Mostly
without lymphovascular inﬁltration. Treated with postoperative vaginal brachytherapy alone, mean dose 24.2Gy (24–40), mean
of 6 fractions. Delimiting organs at risk as the bladder and rectum, with a mean dose of 11.8% and 7.8% respectively. 41.5% had
some degree of mucositis, of these only 3% were G3. In 2.3% of cases occurred surgical scar dehiscence during treatment. 96.9%
live free of disease, free of symptoms in 85.4%. 12.3% have some degree of dyspareunia or vaginal stricture. Only one patient was
treated in a palliative way for an unresectable tumour, staying without illness until date. 1 death for a no speciﬁc cancer reason.
Only 4 patients had recurrence (3.1%), 2 in the lung and 2 locally.
Conclusions. In our series, the recurrence rate is low, but we have found a relation between pathological stage and tumour grade.
Not with tumour size. Vaginal brachytherapy adjuvant to surgery in patients with early stage gynaecologic tumours and low
grade offers excellent overall survival and disease-free with very low toxicity.
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Esophageal cancer (EC) is a rare tumor, very virulent and rarely curable. 50% of patients have metastatic disease at diagnosis and
50% have advanced locoregional disease. Advanced EC is a poor progression-free survival (PFS) in most of patients. Therefore the
treatment intention is palliation rather than curative. High dose rate intraluminal brachytherapy (HDR-ILBRT) allows quick and
lasting palliation and increase local control rates associated with radiochemotherapy (RCHT) in unresectable or advanced EC. The
aim of our study is evaluate symptomatic relief (pain, dysphagia) and local control in terms of PFS in unresectable or advanced
EC treated with HDR-ILBRT. Analyze secondary toxicities and the need for new treatment for recurrent dysphagia. We evaluated
between 2008 and 2012, seven patients diagnosed with unresectable or advanced EC who underwent HDR-ILBRT in our service.
Three of seven patients were treated with palliative brachytherapy (BT) and four received BT associated with RCHT (Boost).
The average dose prescribed for both treatments was 10Gy in 2 fractions, one per week. The variables studied were dysphagia
improvement, pain relief, secondary toxicities, new treatment for recurrent dysphagia and local progression-free survival in
patients treated with BT associated with RCHT. We observed that pain was relieved in all cases, dysphagia improvement in six
of them and only one required PEG. The most common acute toxicity was esophagitis G1 keeping one of them NGT after BT.
There was no bleeding or perforation. Esophageal stricture appeared as late toxicity in one patient at 5 months of completing
treatment. No endoscopic approach was necessary after BT. The mean local PFS time was 4 months for those treated with BT
